Vericel to Host First-Quarter 2015 Earnings Webcast and Conference Call on May 14, 2015
April 30 2015 - 8:00AM
Vericel Corporation (Nasdaq:VCEL), a leading developer of
patient-specific expanded cellular therapies for the treatment of
severe diseases and conditions, today announced the following
webcast and conference call:
What: |
Vericel Corporation First-Quarter 2015
Earnings Call |
When: |
Thursday, May 14, 2015 at 4:30pm (ET) |
Where: |
http://investors.vcel.com/events.cfm |
How: |
The conference call will be available live in
the Investors section of the Vericel website at
http://investors.vcel.com/events.cfm. Please access the site at
least 15 minutes prior to the scheduled start time in order to
download the required audio software if necessary. |
|
|
|
To participate in the live call by telephone,
please call (877) 312-5881 and reference Vericel Corporation
first-quarter 2015 investor conference call. If calling from
outside the U.S., please use the international phone number (253)
237-1173. |
If you are unable to participate in the live call, the webcast
will be available at http://investors.vcel.com/events.cfm until May
14, 2016. A replay of the call will also be available until
11:59 pm (EDT) on May 18, 2015 by calling (855) 859-2056, or from
outside the U.S. (404) 537-3406. The conference ID is
38518920.
About Vericel Corporation
Vericel Corporation (formerly Aastrom Biosciences, Inc.) is a
leader in developing patient-specific expanded cellular therapies
for use in the treatment of patients with severe diseases and
conditions. The company markets two autologous cell therapy
products in the U.S.: Carticel® (autologous cultured chondrocytes),
an autologous chondrocyte implant for the treatment of cartilage
defects in the knee, and Epicel® (cultured epidermal autografts), a
permanent skin replacement for the treatment of patients with
deep-dermal or full-thickness burns comprising greater than or
equal to 30% of total body surface area. Vericel is also
developing MACI™, a third-generation autologous chondrocyte implant
for the treatment of cartilage defects in the knee, and
ixmyelocel-T, a patient-specific multicellular therapy for the
treatment of advanced heart failure due to ischemic dilated
cardiomyopathy. For more information, please visit the
company's website at www.vcel.com.
CONTACT: Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
or
Lee Stern
The Trout Group
lstern@troutgroup.com
(646) 378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024